Genentech and AC Immune Partner Again in Alzheimer’s Disease
By Heather Cartwright
Pharma Deals Review: Vol 2012 Issue 6 (Table of Contents)
Published: 25 Jun-2012
DOI: 10.3833/pdr.v2012.i6.1759 ISSN: 1756-7874
Section: Research & Development
Fulltext:
Abstract
Roche’s Genentech has licensed global rights to develop and commercialise another Alzheimer’s disease antibody programme from AC Immune, this time preclinical antibodies targeting the Tau protein...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS